Last reviewed · How we verify
Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib is a Combination chemotherapy and immunotherapy regimen Small molecule drug developed by University of Ulm. It is currently in Phase 3 development for Multiple myeloma, B-cell non-Hodgkin lymphoma, Waldenström macroglobulinemia.
This combination regimen uses a corticosteroid, B-cell depleting antibody, alkylating agent, and proteasome inhibitor to suppress immune cells and induce apoptosis in malignant plasma cells.
This combination regimen uses a corticosteroid, B-cell depleting antibody, alkylating agent, and proteasome inhibitor to suppress immune cells and induce apoptosis in malignant plasma cells. Used for Multiple myeloma, B-cell non-Hodgkin lymphoma, Waldenström macroglobulinemia.
At a glance
| Generic name | Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib |
|---|---|
| Sponsor | University of Ulm |
| Drug class | Combination chemotherapy and immunotherapy regimen |
| Target | CD20 (rituximab), proteasome (bortezomib), DNA alkylation (cyclophosphamide), glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Dexamethasone is a corticosteroid that suppresses immune function and promotes apoptosis. Rituximab is a monoclonal antibody targeting CD20 on B cells. Cyclophosphamide is an alkylating agent causing DNA damage. Bortezomib is a proteasome inhibitor that triggers apoptosis in plasma cells by preventing protein degradation. Together, these agents target multiple pathways in hematologic malignancies, particularly multiple myeloma and B-cell lymphomas.
Approved indications
- Multiple myeloma
- B-cell non-Hodgkin lymphoma
- Waldenström macroglobulinemia
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Infection
- Neuropathy (bortezomib-related)
- Nausea and vomiting
- Immunosuppression
Key clinical trials
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (PHASE2)
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (PHASE2)
- The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia (PHASE4)
- Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies (EARLY_PHASE1)
- Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia (PHASE3)
- Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders (PHASE2)
- Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma (PHASE1, PHASE2)
- Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib CI brief — competitive landscape report
- Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib updates RSS · CI watch RSS
- University of Ulm portfolio CI
Frequently asked questions about Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
What is Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib?
How does Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib work?
What is Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib used for?
Who makes Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib?
What drug class is Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib in?
What development phase is Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib in?
What are the side effects of Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib?
What does Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib target?
Related
- Drug class: All Combination chemotherapy and immunotherapy regimen drugs
- Target: All drugs targeting CD20 (rituximab), proteasome (bortezomib), DNA alkylation (cyclophosphamide), glucocorticoid receptor (dexamethasone)
- Manufacturer: University of Ulm — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Multiple myeloma
- Indication: Drugs for B-cell non-Hodgkin lymphoma
- Indication: Drugs for Waldenström macroglobulinemia
- Compare: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib vs similar drugs
- Pricing: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib cost, discount & access